Skip to content
HowShorted

Editas Medicine, Inc. short interest in 2020

In 2020, Editas Medicine, Inc.'s disclosed short interest ran from 17.65% of shares outstanding on 15 Jan 2020 to 15.87% on 31 Dec 2020, a change of -1.78 percentage points. The year's high was 18.15% on 15 Oct 2020 and its low 14.15% on 31 Mar 2020, averaging 16.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.15 days on 30 Oct 2020. Full history: Editas Medicine, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Editas Medicine, Inc. in 2020

2020 in figures

Start of year
17.65% (15 Jan 2020)
End of year
15.87% (31 Dec 2020)
Change
-1.78 pp
High
18.15% (15 Oct 2020)
Low
14.15% (31 Mar 2020)
Average
16.10%
Highest days to cover
17.15 (30 Oct 2020)
SEC filings marked
8

Every report in 2020

Editas Medicine, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202017.65%14.54
31 Jan 202017.43%15.41
14 Feb 202015.77%12.28
28 Feb 202014.91%8.1310-K filed, results (8-K)
13 Mar 202015.52%7.73
31 Mar 202014.15%6.39
15 Apr 202014.89%11.26
30 Apr 202014.75%13.55
15 May 202015.00%9.27results (8-K), 10-Q filed
29 May 202015.11%9.50
15 Jun 202016.52%13.02
30 Jun 202017.09%4.93
15 Jul 202016.13%9.25
31 Jul 202014.19%13.46
14 Aug 202014.82%8.01results (8-K), 10-Q filed
31 Aug 202014.72%16.92
15 Sep 202015.64%11.69
30 Sep 202016.82%13.09
15 Oct 202018.15%11.90
30 Oct 202018.12%17.15
13 Nov 202018.05%12.15results (8-K), 10-Q filed
30 Nov 202017.74%16.59
15 Dec 202017.47%3.09
31 Dec 202015.87%2.95

See also: Editas Medicine, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.